Project Grant R43DK146593
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Sojourn Medtech LLC $905,234 on July 15, 2026, to develop and validate CanSim Simulator, a simulator-based training curriculum for hemodialysis cannulation skills targeted at dialysis patient care technicians and nurses. CanSim Simulator integrates hardware and software with realistic vascular access models to standardize competency-based training and skill assessment for arteriovenous fistula cannulation. The device...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Kscube, LLC $315,335 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a real-time, non-invasive urinary oxygen monitoring system for acute kidney injury prevention. The recipient will advance development of a novel continuous kidney-stress monitor for use during surgery and in intensive care units. The technology provides real-time detection of...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Minnesota Healthsolutions Corporation $628,558 on September 12, 2025, to develop and evaluate an innovative dialysis cannulation needle designed to reduce accidental needle infiltration injury during hemodialysis. The award funds work under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), which supports extramural biomedical research that improves understanding of disease...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Regents of the University of California, San Francisco $202,375 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a block copolymer-based urea adsorbent dialysate regeneration cartridge for an intracorporeal hemodialysis system. The research investigates an external dialysate system featuring a dialysate regeneration...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services, awarded Silq Technologies Corporation $320,965 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Silq will develop a zwitterion-treated ureteral stent designed to reduce device-related complications in patients with ureteral obstructions. The work encompasses three aims: developing the zwitterion-treated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of California, San Francisco $2,198,203 on September 24, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on modernizing clinical methods for assessing fluid excess removal during in-center hemodialysis treatment. The project addresses the long-standing practice of "dry weight" assessment—a trial-and-error...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Daecos LLC $619,274 on August 6, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate an artificial intelligence-driven clinical decision support system for predicting acute dialysis needs in critically ill patients. Daecos will refine its proprietary algorithms using retrospective data from three UC San Diego hospitals, deploy the system within UC...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Angiotensin Therapeutics Inc. $314,355 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a bioengineered soluble ACE2 protein therapeutic for delayed graft function in kidney transplantation. Delayed graft function affects up to 50 percent of deceased-donor kidney transplant recipients and is caused by acute proximal tubular injury from...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Emory University $1.594 million on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a prospective longitudinal cohort study characterizing quality-of-life experiences among 221 home dialysis patients and their family caregivers. The study will examine how patients and caregivers incorporate peritoneal dialysis and home hemodialysis into daily...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Leland Stanford Junior University $169,991 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a quasi-experimental evaluation of Medicare Advantage enrollment effects on dialysis care and outcomes. The research addresses a critical evidence gap created when the 21st Century Cures Act lifted the prohibition on Medicare Advantage enrollment for...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Silicon Kidney LLC $354,500 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an Intracorporeal Hemodialysis System (IHEMO) enabling home hemodialysis for end-stage kidney disease patients. Silicon Kidney LLC will develop and advance toward commercialization an implanted hemodialyzer (hemocartridge) that creates permanent vascular connections between a patient's vasculature and the device, eliminating the need for daily self-cannulation and associated risks of needle dislodgement and exsanguination. The system simplifies home hemodialysis by allowing patients to attach transcutaneous dialysate ports to the implanted hemocartridge, reducing operator error and barriers to frequent and prolonged intensive hemodialysis. This innovation addresses adoption barriers that have kept intensive hemodialysis—which offers survival rates comparable to kidney transplant—to fewer than 2 percent of the end-stage kidney disease population. The award period runs from September 1, 2026, through August 31, 2027, with work performed in San Ramon, California. Silicon Kidney LLC is a self-certified small disadvantaged business specializing in silicon nanopore membrane technology for biomedical applications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $354.5k | 8/25/26 |